Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Neurology

Volumn 68, Issue 16, 2007, Pages 1299-1304

  Balcer, L J ^a   Galetta, S L ^a   Calabresi, P A ^b   Confavreux, C ^c   Giovannoni, G ^d   Havrdova, E ^e   Hutchinson, M ^f   Kappos, L ^g   Lublin, F D ^h   Miller, D H ^r   O'Connor, P W ⁱ   Phillips, J T ^j   Polman, C H ^k   Radue, E W ^g   Rudick, R A ^l   Stuart, W H ^m   Wajgt, A ⁿ   Weinstock Guttman, B ^o   Wynn, D R ^p   Lynn, F ^q   Panzara, M A ^q   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HÔPITAL NEUROLOGIQUE   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j Multiple Sclerosis Center at Texas Neurology   (United States)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l LERNER RESEARCH INSTITUTE   (United States)

^m MS Center of Atlanta   (United States)

ⁿ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^o JACOBS NEUROLOGICAL INSTITUTE   (United States)

^p Multiple Sclerosis Center   (United States)

^q BIOGEN   (United States)

^r 3 East Gates Building ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; VISION; VISION TEST; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 34247211800     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000259521.14704.a8     Document Type: Article

References (36)

1. Balcer LJ. Multiple sclerosis and related demyelinating diseases. In: Miller NR, Newman NJ, Biousse V, Kerrison JB, eds. Walsh and Hoyt's clinical neuro-ophthalmology. vol. 3, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:3429-3525.
2. Sørensen TL, Frederiksen JL, Brønnum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology 1999;53:473-478.
3. Balcer LJ. Optic neuritis. N Engl J Med 2006;354:1273-1280.
4. Ma SL, Shea JA, Galetta SL, et al. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol 2002;133:686-692.
5. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40:469-479.
6. Rudick RA, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379-382.
7. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
8. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
9. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005;64:992-995.
10. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003;61:1367-1373.
11. Balcer LJ, Baier ML, Pelak VS, et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler 2000;6:163-171.
12. Weinstock-Guttman B, Baier M, Stockton R, et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Mult Scler 2003;9:529-534.
13. Klein R, Klein BEK, Moss SE, DeMets D. Inter-observer variation in refraction and visual acuity measurement using a standardized protocol. Ophthalmology 1983;90:1357-1359.
14. Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-96.
15. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006;113:324-332.
16. Osborne B, Jacobs D, Markowitz C, et al. Relation of macular volume to retinal nerve fiber layer thickness and visual function in multiple sclerosis. Neurology 2006;66(suppl 2):A14.
17. Wu GF, Schwartz ED, Jacobs DA, et al. Regional MRI abnormalities and visual dysfunction in patients with multiple sclerosis. Presented at the North American Neuro-Ophthalmology Society Annual Meeting, Tucson, AZ, 2006, abstract available at www.nanosweb.org.
18. NASA/MS Cooling Study Group. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 2003;60:1955-1960.
19. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
20. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
21. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
22. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-933.
23. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
24. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
25. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.
26. Complications of Age-related Macular Degeneration Prevention Trial (CAPT): Manual of Operations, 2000 [online]. Available at: www.med.upenn.edu/ cpob/studies/documents/MOP_JULY_2000.EP.pdf.
27. Rubin GS, Munoz B, Bandeen-Roche K, West SK. for the SEE project team. Monocular vs. binocular visual acuity as measures of vision impairment and predictors of visual disability. Invest Ophthalmol Vis Sci 2000;41:3327-3334.
28. Azen SP, Varma R, Preston-Martin S, et al. Binocular visual acuity summation and inhibition in an ocular epidemiological study: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2002;43:1742-1748.
29. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
30. Rosser DA, Cousens SN, Murdoch IE, et al. How sensitive to clinical change are ETDRS and logMAR visual acuity measurements? Invest Ophthalmol Vis Sci 2003;44:3278-3281.
31. Kupersmith MJ, Nelson JI, Seiple WH, et al. The 20/20 eye in multiple sclerosis. Neurology 1983;33:1015-1020.
32. Regan D, Neima D. Low-contrast letter charts as a test of visual function. Ophthalmology 1983;90:1192-1200.
33. Beck RW, Cleary PA, Anderson MM Jr, et al. Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-588.
34. Beck RW, Kupersmith MJ, Cleary PA, Katz B. Fellow eye abnormalities in acute unilateral optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology 1993;100:691-697.
35. Freeman EE, Muñoz B, Turano KA, West SK. Measures of visual function and their association with driving modification in older adults. Invest Ophthalmol Vis Sci 2006;47:514-520.
36. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the perception of 'real-world' targets. Br J Ophthalmol 1987;71:791-796.